Today we welcome Manuel Hidalgo Medina, MD, PhD to our board of directors. Dr. Hidalgo's extensive experience in precision oncology and dedication to advancing cancer care will further strengthen us as we push forward in our mission to conquer cancer with data.
About us
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.
- Website
-
http://www.guardanthealth.com/
External link for Guardant Health
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Palo Alto, California
- Type
- Public Company
- Founded
- 2012
Locations
Employees at Guardant Health
Updates
-
Len Lichtenfeld MD MACP emphasizes the urgent need for new colorectal cancer (CRC) screening options in his latest article for Healthcare Innovation . As we strive for improved patient outcomes and accessibility, exploring innovative approaches is essential. Read more of this important perspective.
It’s Time for a New Option in Colorectal Cancer Screening
hcinnovationgroup.com
-
Passionate about gaining access to standardized, robust liquid biopsy testing globally? Join us for a discussion with Jean-Francois Martini, head of biomarker clinical assay and technology at Pfizer, and Lawrence Wang, chief financial officer at Adicon Clinical Laboratories to hear about the importance of LBx testing for global clinical trials and how we're successfully enabling in-country testing. 📅 Date: July 25 🕦 Time: 11:30am ET Registration: bit.ly/3XXGBnU
-
Via STAT: Blood tests for cancer patients are proving to be life-saving, but accessibility remains an issue. Our co-CEO Helmy Eltoukhy outlines the barriers and why ensuring equitable access is essential to improving patient outcomes.
Blood Tests for Cancer Patients Save Lives. Access Remains an Issue.
https://www.statnews.com
-
Colorectal cancer is highly treatable if caught early. Yet, despite having screening options available, a staggering 50 million people – approximately one in three eligible Americans – are not up to date with recommended screening. Recently an FDA committee endorsed a new blood test as a primary non-invasive screening option. It has the potential to motivate more patients to be screened and ultimately save more lives. We, the undersigned, urge policymakers, health care professionals, and our fellow advocates to rally behind this groundbreaking technology and give patients more screening options. Signatories: Colorectal Cancer Alliance, Alliance for Women's Health & Prevention, Cancer Advocacy Group of Louisiana (CAGLA), Colon Cancer Stars, First Ladies Health Initative, Global Colon Cancer Association, GI Cancers Alliance, MAN UP TO CANCER, The Raymond Foundation, Inc., Colon Cancer Coalition, PALTOWN Development Foundation, The Blue Hat Foundation, One Cancer Place
Don't Let Perfect Become the Enemy of Good in Colorectal Cancer Screening
thehill.com
-
Catch our chief medical officer Dr. Craig Eagle at Collision Conf this Thursday for a panel discussion on the current state of cancer detection and what developments to expect over the next decade and beyond.
-
In a development that could help address the colorectal cancer screening gap, an FDA panel of experts recently recommended the approval of Shield, our innovative blood test, for primary, non-invasive screening in average-risk adults aged 45 and older. Read more about the FDA panel's recommendation and the future of colorectal cancer screening.
FDA Advisory Committee Strongly Recommends Approval For Guardant Health Blood Test For Colorectal Cancer
guardanthealth.com
-
We have launched our upgraded Guardant360 TissueNext test featuring an expanded gene panel of 498 biomarkers and a faster turnaround time for results. “In addition to identifying guideline-recommended biomarkers, the upgraded test now provides more comprehensive gene coverage, so oncologists can make better informed decisions about the optimal treatment strategy for their patients with advanced cancer…” said co-CEO Helmy Eltoukhy.
Guardant introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
investors.guardanthealth.com
Similar pages
Browse jobs
Stock
GH
NASDAQ
20 minutes delay
$30.75
-0.4 (-1.284%)
- Open
- 31.39
- Low
- 30.56
- High
- 31.73
Data from Refinitiv
See more info on